Clinical Trial Update: Study of Atomoxetine in the Prevention of Vasovagal Syncope [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating atomoxetine for the prevention of vasovagal syncope is currently recruiting, with the University of Calgary as sponsor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vasovagal Syncope

Drugs mentioned

• Atomoxetine (Atomoxetine)

Snippet

Sponsor: University of Calgary | Conditions: Vasovagal Syncope | Phase 3 | Status: RECRUITING